Department of Urology, Hopital Pontchaillou, University of Rennes, 2 rue Henri Le Guilloux, 35000, Rennes, France.
Department of Biochemistry, University of Rennes, Rennes, France.
World J Urol. 2020 Sep;38(9):2261-2268. doi: 10.1007/s00345-019-03016-x. Epub 2019 Nov 18.
The aim of this study was to investigate the disease-specific urinary levels variations of neurotrophins (NGF, BDNF), mediators of inflammation (TGFβ-1, PGE-2) and markers of extracellular matrix alterations (TIMP-2) in patients with multiple sclerosis (MS) spinal cord injury (SCI), or spina bifida (SB), and neurogenic detrusor overactivity (NDO).
A prospective single-center study was conducted between March 2015 and March 2017. Patients aged over 18 years old, with neurological disease, with a urodynamic diagnosis of NDO were included. The urinary levels of NGF, BDNF, TIMP-2, PGE 2, and TGF-β1 were measured using dedicated ELISA kits.
Forty-one patients were included: 6 with MS, 20 with SCI, and 15 with spina bifida. The average urinary level of NGF/Cr was significantly higher in MS patients compared to other neurologic populations (8 vs. 0.56 vs. 1.25 pg/mg of creatinine; p = 0.001) as well for the average urinary level of BDNF (88.3 vs. 5 vs. 4.8 pg/mg of creatinine; p < 0.0001). SCI patients had a significantly lower level of TGFβ-1 than SB patients (p = 0.04). The urinary level of PGE2 was significantly correlated with the Body Mass Index (r = 0.61; p = 0.0002).
All NDO may not be created equal from the molecular standpoint. Multiple sclerosis patients had higher urinary levels of neurotrophins than in other neurologic populations with NDO. Urinary TGFβ-1, a strong determinant of extracellular matrix, was significantly higher in spina bifida patients compared to SCI patients. These findings underscore the importance of using and interpreting those possible urinary markers in a disease-specific fashion.
本研究旨在探讨多发性硬化症(MS)脊髓损伤(SCI)或脊膜膨出(SB)伴神经源性逼尿肌过度活动(NDO)患者尿神经生长因子(NGF)、脑源性神经营养因子(BDNF)、炎症介质(TGFβ-1、PGE-2)和细胞外基质改变标志物(TIMP-2)的疾病特异性尿水平变化。
这是一项 2015 年 3 月至 2017 年 3 月进行的前瞻性单中心研究。纳入年龄大于 18 岁、患有神经疾病、尿动力学诊断为 NDO 的患者。使用专用 ELISA 试剂盒测量尿 NGF、BDNF、TIMP-2、PGE2 和 TGF-β1 的水平。
共纳入 41 例患者:MS 患者 6 例、SCI 患者 20 例、SB 患者 15 例。MS 患者尿 NGF/Cr 平均水平明显高于其他神经疾病患者(8 比 0.56 比 1.25pg/mg 肌酐;p=0.001),BDNF 平均水平(88.3 比 5 比 4.8pg/mg 肌酐;p<0.0001)也较高。SCI 患者的 TGFβ-1 水平明显低于 SB 患者(p=0.04)。PGE2 尿水平与体重指数呈显著正相关(r=0.61;p=0.0002)。
从分子角度来看,并非所有 NDO 都相同。MS 患者的神经生长因子尿水平高于其他伴有 NDO 的神经疾病患者。TGFβ-1 是细胞外基质的一个重要决定因素,在 SB 患者中明显高于 SCI 患者。这些发现强调了以疾病特异性方式使用和解释这些可能的尿标志物的重要性。